spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:   RNA  

 HSMN NewsFeed - 10 Apr 2026
Vivatides Therapeutics Announces Oversubscribed $54 Million Series A Financing to Accelerate Extrahepatic RNA Therapeutics Development
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 27 Jan 2025
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Dec 2009
Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company
Biopharmaceuticals Mergers & Acquisitions Personnel
 HSMN NewsFeed - 26 Jun 2007
Alnylam Initiates Phase II Clinical Trial to Evaluate Safety and Anti-viral Efficacy of ALN-RSV01 in the Treatment of Respiratory Syncytial Virus (RSV) Infection
Biopharmaceuticals
 HSMN NewsFeed - 17 Apr 2007
Alnylam Announces Advancement of a New RNAi Therapeutic Development Program for the Treatment of Liver Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Apr 2007
Exciting Developments on the Horizon for Parkinson Disease, Says Medical Director for the National Parkinson Foundation
Biopharmaceuticals Regenerative Medicine Neurology
 HSMN NewsFeed - 8 Jan 2007
Alnylam Announces Key Product and Business Goals for 2007
Biopharmaceuticals
 HSMN NewsFeed - 5 Dec 2006
Alnylam Advances a Systemically Delivered RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia as New Development Program
Biopharmaceuticals
 HSMN NewsFeed - 28 Nov 2006
Alnylam Initiates Clinical Program to Evaluate Anti-Viral Activity for ALN-RSV01, an RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection
Biopharmaceuticals
 HSMN NewsFeed - 20 Sep 2006
Biogen Idec and Alnylam Form Alliance to Discover and Develop Therapeutics for the Potential Treatment of Progressive Multifocal Leukoencephalopathy (PML)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 24 May 2006
Alnylam Grants Bioneer License to Kreutzer-Limmer Patents for the RNA Interference (RNAi) Research Products Market
Biopharmaceuticals Licensing
Return to NewsFeed  

 Additional items found! 21

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 21 additional stories matching:
RNA
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!